Comparative proteomics analysis of the antitumor effect of CIGB-552 peptide in HT-29 colon adenocarcinoma cells-Reference-Cited by-同舟云学术

Comparative proteomics analysis of the antitumor effect of CIGB-552 peptide in HT-29 colon adenocarcinoma cells

Published:2015-08 Issue: Volume:126 Page:163-171
ISSN:1874-3919
Container-title:Journal of Proteomics
language:en
Short-container-title:Journal of Proteomics

Author:

Núñez de Villavicencio-Díaz Teresa,Ramos Gómez Yassel,Oliva Argüelles Brizaida,Fernández Masso Julio R.,Rodríguez-Ulloa Arielis,Cruz García Yiliam,Guirola-Cruz Osmany,Perez-Riverol Yasset,Javier González Luis,Tiscornia Inés,Victoria Sabina,Bollati-Fogolín Mariela,Besada Pérez Vladimir,Guerra Vallespi Maribel

Publisher

Elsevier BV

Subject

Biochemistry,Biophysics

Reference57 articles.

1. Isolation and biological activities of limulus anticoagulant (anti-LPS factor) which interacts with lipopolysaccharide (LPS);Morita;J. Biochem.,1985

2. Crystal structure of an endotoxin-neutralizing protein from the horseshoe crab, Limulus anti-LPS factor, at 1.5A resolution;Hoess;EMBO J.,1993

3. A Limulus antilipopolysaccharide factor-derived peptide exhibits a new immunological activity with potential applicability in infectious diseases;Vallespi;Clin. Diagn. Lab. Immunol.,2000

4. Identification of a novel antitumor peptide based on the screening of an Ala-library derived from the LALF(32–51) region;Vallespi;J. Pept. Sci.,2010

5. The antitumor peptide CIGB-552 increases COMMD1 and inhibits growth of human lung cancer cells;Fernández Massó;J. Amino Acids,2013

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Organotin benzohydroxamate derivatives (OTBH) target colchicine-binding site exerting potent antitumor activity both in vitro and vivo revealed by quantitative proteomic analysis;European Journal of Pharmaceutical Sciences;2023-08

2. Cell-Translocation Mechanisms of CPPs;CPP, Cell-Penetrating Peptides;2023

3. Synergic effect of anticancer peptide CIGB-552 and Cisplatin in lung cancer models;Molecular Biology Reports;2022-01-30

4. Formulation matters! A spectroscopic and molecular dynamics investigation on the peptide CIGB552 as itself and in its therapeutical formulation;Journal of Peptide Science;2021-06-10

5. A first‐in‐class, first‐in‐human, phase I trial of CIGB ‐552, a synthetic peptide targeting COMMD1 to inhibit the oncogenic activity of NF‐κB in patients with advanced solid tumors;International Journal of Cancer;2021-05-27